LEADING SMALL TEAM IN WASHINGTON, D.C. JOINS TTR SOTHEBY’S INTERNATIONAL REALTY
Luxury Real Estate Team Brings $2.42 Billion in Sales and Nearly 1,300 Transactions to Premier Brokerage WASHINGTON, March 27, 2025 /PRNewswire/ — Sotheby’s... Read more.
MAYOR BRANDON JOHNSON ANNOUNCES BUILD BETTER TOGETHER
This new initiative showcases and advances economic development, including growth, quality housing, businesses, jobs, lifestyle and cultural improvements for Chicagoans... Read more.
Allot Files Annual Report on Form 20-F for the Year Ended December 31, 2024
HOD HASHARON, Israel, March 27, 2025 /PRNewswire/ — Allot Ltd. (Nasdaq: ALLT) (TASE: ALLT), a leading global provider of innovative network intelligence and... Read more.
Pinegrove Venture Partners Announces Expanded Relationship with Florida State Board of Administration (SBA)
$700M Commitment to Drive Innovation in the Global Venture Ecosystem SAN FRANCISCO, March 27, 2025 /PRNewswire/ — Pinegrove Venture Partners (Pinegrove) is... Read more.
EPSIUM ENTERPRISE LIMITED Announces Closing of US$5.0 Million Initial Public Offering
MACAU, March 27, 2025 /PRNewswire/ — EPSIUM ENTERPRISE LIMITED (Nasdaq: EPSM) (the “Company” or “EPSIUM”), a company engaged in importing... Read more.
Supermicro Ships Over 20 New Systems that Redefine Single-Socket Performance and Deliver Data Center Power, Space, and Cost Savings
New system architectures support Intel® Xeon® 6 with P-Cores, providing up to 136 PCIe 5.0 lanes and expanding possibilities for high-speed networking, GPUs,... Read more.
Driven Tech Named to the Prestigious CRN Tech Elite 250 for 2025
NEW YORK, March 27, 2025 /PRNewswire/ — Driven Tech Inc., DBA Driven Technologies, today announced that CRN, a brand of The Channel Company, has recognized... Read more.
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
– Three INDs cleared by US FDA for TYRA’s proprietary precision small molecules – – TYRA-300 to be evaluated in three Phase 2 studies: SURF302... Read more.
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience... Read more.
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration... Read more.